Bausch Health’s OraPharma marks 25 years of Arestin

The only FDA-approved topical antibiotic used with scaling and root planing (SRP) marks a quarter century of clinical use

LAVAL, QC, February 19, 2026 /PRNewswire/ — Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) and its dental products business, OraPharma, today announced the milestone 25th anniversary of Microspheres ARESTIN® (minocycline HCl), 1 mg, a topical antibiotic used as an adjunct to root reduction. depth in adult patients with periodontitis. ARESTIN is backed by over two decades of clinical experience and remains the only FDA-approved topical antibiotic for this use.

Dan Wu, Ph.D., Senior Director, Pharmaceutical Sciences & Technology, Bausch Health, and a member of the development team behind ARESTIN, reflected, “The ‘why’ behind the development of ARESTIN began with the recognition that periodontal disease is a localized, chronic bacterial condition and that clinicians did not have a targeted way to help treat it. delivering antibiotic treatment directly to the periodontal pocket, using tiny microspheres that release the antibiotic gradually over time before naturally biodegrading.”

Periodontal disease remains one of the most prevalent chronic oral health conditions worldwide, affecting more than a billion people¹. As part of comprehensive periodontal disease management, many dental professionals have incorporated ARESTIN with scaling and root planing (SRP).

“Reaching Arestin’s 25-year milestone as the only FDA-approved topical antibiotic reflects our commitment to periodontal care,” said Tom Stern, Vice President and General Manager of the OraPharma business, the dental division of Bausch Health. “As we recognize this legacy, we are equally focused on the future—one defined by innovation and deeper collaboration with the dental community. Building on Arestin’s impressive track record, we continue to champion non-surgical periodontal therapy for deserving patients.”

OraPharma continues to advance its commitment to periodontal health, including recent commercial expansion Canada and Puerto Rico with the aim of improving access to treatment options in areas with unmet needs.

What is ARESTIN?
ARESTIN® (minocycline HCl) Microspheres, 1 mg is used in conjunction with scaling and root planing (SRP) procedures to treat patients with adult periodontitis (gingivitis). ARESTIN® can be used as part of a general oral health program that includes good brushing and flossing habits and SRP.

IMPORTANT SAFETY INFORMATION

• heyo do not use ARESTIN if you are allergic to minocycline or tetracyclines, ask your dentist if you are not sure. Do not use ARESTIN in children, pregnant or lactating women, as the use of tetracycline class drugs, including ARESTIN, during tooth development may cause permanent tooth discoloration.
• ARESTIN may make you sensitive to sunlight. Patients exposed to direct sunlight or UV light may develop severe sunburn. At the first sign of skin redness, call your dentist.
• Serious allergic reactions have occurred with oral minocycline. Get emergency help right away if you develop any signs of an allergic reaction, such as shortness of breath, swelling of the face, throat, and tongue, rash, hives, itching, fever, or enlarged lymph nodes.
• Tetracyclines, including oral minocycline, have been associated with the development of autoimmune syndromes with symptoms such as joint pain, muscle pain, rash, swelling, fever, enlarged lymph nodes, and general body weakness.
• Tell your dentist about any medicines you take and any health problems you have, including whether you have had oral candidiasis (“thrush”).
• ARESTIN has not been studied in patients with weakened immune systems, such as patients with HIV infections or diabetes, or in patients receiving chemotherapy or radiation.
• The most commonly reported non-dental side effects were headache, infection, flu-like symptoms, and pain.

We encourage you to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please click here for complete prescribing information.

About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) is a global, diversified pharmaceutical company that enriches lives through our relentless pursuit of better healthcare outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health through our control of Bausch + Lomb Corporation. Our ambition is to be a global integrated healthcare company trusted and valued by patients, physicians, employees and investors. OraPharma is a specialty pharmaceutical company committed to working with dental professionals to improve oral health. More information can be found at www.orapharma.com. For more information about Bausch Health, visit www.bauschhealth.com and connect with us LinkedIn.

Forward-looking statements
This news release may contain forward-looking statements within the meaning of applicable securities laws, including the Safe Harbor provisions of US Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be qualified by the use of the words “will”, “expects”, “hopes”, “expects”, “intends”, “plans”, “should”, “could”, “could”, “may”, “believes” or similar expressions. These statements are not historical facts or assurances of future performance, are based on management’s current expectations and beliefs, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties related more broadly to Bausch Health’s overall business, including those more fully described in Bausch Health’s most recent annual and quarterly reports and described from time to time in Bausch Health’s other filings with US Securities and Exchange Commission and the Canadian Securities Administrators, which agents are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update any of these forward-looking statements to reflect events, information or circumstances after the date of this announcement or to reflect actual results, except as required by law.

REFERENCE:
⁽¹⁾ Hu M, Zhang R, Wang R, Wang Y, Guo J. Global, regional and national burden of periodontal disease from 1990 to 2021 and projections to 2040: an analysis of the Global Burden of Disease Study 2021. Front Oral Health. 2025? 6:1627746. doi:10.3389/froh.2025.1627746. [frontiersin.org]

ARESTIN is a trademark of Bausch Health Companies Inc. or its subsidiaries.
© 2026 Bausch Health Companies Inc. or its subsidiaries.

View original content for downloading media:https://www.prnewswire.com/news-releases/bausch-healths-orapharma-celebrates-25-years-of-arestin–minocycline-hcl-microspheres-302691824.html

SOURCE Bausch Health Companies Inc.